• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Mark Cuban's Cost Plus Drug Co. Expands to Offer J&J Brand-Name Medications

Article

Cost Plus Drug Co. adds J&J's Janssen medications to its offerings, increasing affordability for diabetes patients.

Mark Cuban's Cost Plus Drug Co. has expanded its offerings to include brand-name medications from J&J subsidiary Janssen. The online wholesaler now sells three Janssen products, Invokana, Invokamet, and Invokamet XR, at significantly reduced prices compared to market rates.

Taking the Direct Path | ©danleap | Adobe Stock

Invokana, a highly effective medication for Type 2 diabetes, typically comes with a hefty price tag of over $675, as stated on Cost Plus Drugs' website. However, with Cuban's enterprise entering the scene, one can now access this vital treatment for a significantly reduced cost of just $243.90.

"This arrangement with Mark Cuban Cost Plus Drug Company is another example of how we [at Janssen] are supporting patient access to needed medicines especially for cash paying patients who are uninsured, or who are underinsured because of cost-shifting by commercial payers." a Janssen spokesperson stated in an emailed statement to The Street. "We have long-standing, strong relationships with all stakeholders across the healthcare system, including with PBMs, that are integral to our efforts to help us maintain market access for our products.”

Reference: Mark Cuban Has Good News for People with Diabetes | April 9, 2023 | Luc Olinga, TheStreet

Reference: Cuban's pharmacy picks up J&J brand-name drugs | April 4, 2023 | Becker's Hospital Review

Recent Videos
Related Content